Abstract

NANOTECHNOLOGY-BASED FORMULATION OF GANAXOLONE FOR ENHANCED TREATMENT OF SEIZURES DESIGN AND DEVELOPMENT APPROACH

Sk Md Ajhar Ali*, Dr. Santosh Kumar Panda and Subhakanta Kanungo

.

Abstract

Ganaxolone is a promising antiepileptic drug that suffers from poor solubility, bioavailability, and rapid clearance from the body. Nanotechnology-based drug delivery systems have emerged as a promising approach to overcome these challenges.[1,3] In this study, we developed a novel Ganaxolone formulation utilizing nanotechnology to enhance its therapeutic efficacy. Polymeric nanoparticles were synthesized through a bottom-up approach and used as a carrier system for Ganaxolone. The synthesized nanoparticles were characterized for size, surface charge, and drug release kinetics.[13,17] The optimized formulation was evaluated for its efficacy in vitro and in vivo in animal models of seizures. Our results demonstrated that the developed Ganaxolone nanoparticles had a desirable particle size, surface charge, and sustained drug release kinetics.[11] In vitro studies demonstrated enhanced cellular uptake and antiepileptic efficacy compared to free Ganaxolone.[6] In vivo studies demonstrated that the optimized formulation resulted in a significant reduction in seizure frequency and severity compared to free Ganaxolone. Furthermore, the formulation showed improved pharmacokinetics, with a prolonged half-life and increased brain distribution.[14] These findings demonstrate the potential of nanotechnology-based drug delivery systems for enhancing the therapeutic efficacy of Ganaxolone for the treatment of seizures.

Keywords: Nanotechnology-based formulation, Ganaxolone nanoparticles, Enhanced treatment, Seizures, Design and development approach.